Akhil Kapoor, Professor of Medical Oncology at Tata Memorial Centre, shared a post on LinkedIn:
“Pleased to share our publication in JCO Oncology Advances:
‘Impact of Trastuzumab on Survival Outcomes in HER2-Positive Biliary Tract Cancers: A Real-World Analysis From a High-Incidence Region (REAL TAB)’.
In a retrospective analysis of 91 patients with HER2-positive biliary tract cancers (mostly gallbladder cancer), trastuzumab-based therapy was associated with improved outcomes:
2-year OS: 32.7% vs 11.8%
These results support routine HER2 testing and highlight the real-world value of precision oncology in biliary tract cancers.
Thank you to all patients, co-authors, collaborators, and multidisciplinary teams who made this work possible.”
Title: Impact of Trastuzumab on Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Cancers: A Real-World Analysis From a High-Incidence Region (REAL TAB)
Authors: Anuj Gupta, Bal Krishna Mishra, Bipinesh Sansar, Ayushi Pragya, Ravindra Kumar, Arpita Singh, Ankita Pal, Arvind Upadhyay, Zachariah Chowdhury, Ipsita Dhal, Himani Rai, Neha Singh, Shreya Shukla, Lincoln Pujari, Somnath Dey, Mayank Tripathi, Akhil Kapoor
Other articles Akhil Kapoor on OncoDaily